Table 2 Baseline characteristics of the patients enrolled in the cohorts. Training and testing groups are characterized by mean ± standard derivation (SD) and range from minimal to maximal value or as categorical, if applicable

Gender [men/women]

8/38

2/10

Age at biopsy [years]

35.50 ± 14.06

38.17 ± 14.06

LN class II/III/IV/V/VI

1/10/21/9/5

0/2/4/3/3

Number of glomeruli in specimen

20.83 ± 10.21

18.08 ± 6.26

Number of totally sclerotic glomeruli

1.61 ± 3.08

2.92 ± 4.68

Number of partially sclerotic glomeruli

3.95 ± 7.79

3.25 ± 3.93

Number of cellular/cellular-fibrotic crescents

1.43 ± 3.07

0.50 ± 1.45

Number of glomeruli with fibrillary necrosis

2.52 ± 4.85

1.58 ± 2.07

Number of glomeruli without changes

1.09 ± 2.50

0.25 ± 0.87

Activity Index

8.99 ± 4.77

8.83 ± 3.51

Chronicity Index

2.95 ± 1.91

3.92 ± 2.78

Interstitial fibrosis [%]

9.02 ± 5.74

13.33 ± 10.73

WBC [10^3/ul]

8.09 ± 3.26

7.34 ± 1.81

NEU [10^3/ul]

5.49 ± 2.61

5.60 ± 2.09

LYM [10^3/ul]

1.90 ± 0.95

1.28 ± 0.71

NLR

3.90 ± 4.06

6.42 ± 5.05

HGB [g/dl]

12.06 ± 1.82

11.26 ± 1.19

PLT [10^3/ul]

238.35 ± 79.15

197.92 ± 70.78

PLR

176.80 ± 147.66

219.48 ± 132.10

ERS [mm/1 h]

37.75 ± 24.92

28.27 ± 15.11

CRP [mg/dl]

4.59 ± 8.67

2.16 ± 2.70

sCr [mg/dl]

1.27 ± 0.69

1.32 ± 0.48

eGFR [ml/min/1.73 m²]

67.98 ± 26.65

57.08 ± 26.05

TP [g/dl]

5.35 ± 0.95

5.23 ± 0.89

Albumin [g/dl]

2.87 ± 0.58

2.82 ± 0.52

Total Cholesterol [mg/dl]

274.77 ± 80.20

243.48 ± 89.49

Triglycerides [mg/dl]

202.75 ± 114.55

171.70 ± 68.39

C3 [g/l]

0.86 ± 0.29

0.76 ± 0.29

C4 [g/l]

0.18 ± 0.09

0.16 ± 0.12

ANA (0/1/undefined)

1/39/6

2/9/1

Erythrocyturia [RBC/HPF]

10/19/17

3/4/5

UPCR [mg/mg]

2.91 ± 2.12

4.76 ± 4.83

Target - CR [1/0]

14/32

4/8